-
1
-
-
84945438141
-
The epidemiology of psoriatic arthritis
-
Ogdie, A, Weiss, P, The epidemiology of psoriatic arthritis. Rheum Dis Clin North Am 41 (2015), 545–568.
-
(2015)
Rheum Dis Clin North Am
, vol.41
, pp. 545-568
-
-
Ogdie, A.1
Weiss, P.2
-
2
-
-
14244260176
-
Psoriatic arthritis: epidemiology, clinical features, course, and outcome
-
Gladman, DD, Antoni, C, Mease, P, Clegg, DO, Nash, P, Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 64 (2005), ii14–ii17.
-
(2005)
Ann Rheum Dis
, vol.64
, pp. ii14-ii17
-
-
Gladman, D.D.1
Antoni, C.2
Mease, P.3
Clegg, D.O.4
Nash, P.5
-
3
-
-
84927802334
-
Extra-articular manifestations in psoriatic arthritis patients
-
Peluso, R, Iervolino, S, Vitiello, M, Bruner, V, Lupoli, G, Di Minno, MN, Extra-articular manifestations in psoriatic arthritis patients. Clin Rheumatol 34 (2015), 745–753.
-
(2015)
Clin Rheumatol
, vol.34
, pp. 745-753
-
-
Peluso, R.1
Iervolino, S.2
Vitiello, M.3
Bruner, V.4
Lupoli, G.5
Di Minno, M.N.6
-
4
-
-
85037581361
-
The effects of structural damage on functional disability in psoriatic arthritis
-
Kerschbaumer, A, Baker, D, Smolen, JS, Aletaha, D, The effects of structural damage on functional disability in psoriatic arthritis. Ann Rheum Dis 76 (2017), 2038–2045.
-
(2017)
Ann Rheum Dis
, vol.76
, pp. 2038-2045
-
-
Kerschbaumer, A.1
Baker, D.2
Smolen, J.S.3
Aletaha, D.4
-
5
-
-
85046841562
-
Quality of life in psoriatic arthritis
-
Gudu, T, Gossec, L, Quality of life in psoriatic arthritis. Exp Rev Clin Immunol 14 (2018), 405–417.
-
(2018)
Exp Rev Clin Immunol
, vol.14
, pp. 405-417
-
-
Gudu, T.1
Gossec, L.2
-
6
-
-
85041908087
-
Cost and cost effectiveness of treatments for psoriatic arthritis: a systematic literature review
-
D'Angiolella, LS, Cortesi, PA, Lafranconi, A, et al. Cost and cost effectiveness of treatments for psoriatic arthritis: a systematic literature review. PharmacoEconomics 36 (2018), 567–589.
-
(2018)
PharmacoEconomics
, vol.36
, pp. 567-589
-
-
D'Angiolella, L.S.1
Cortesi, P.A.2
Lafranconi, A.3
-
7
-
-
84936989259
-
The indirect costs of psoriatic arthritis: systematic review and meta-analysis
-
Kawalec, P, Malinowski, KP, The indirect costs of psoriatic arthritis: systematic review and meta-analysis. Expert Rev Pharmacoecon Outcomes Res 15 (2015), 125–132.
-
(2015)
Expert Rev Pharmacoecon Outcomes Res
, vol.15
, pp. 125-132
-
-
Kawalec, P.1
Malinowski, K.P.2
-
8
-
-
84960126976
-
European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update
-
Gossec, L, Smolen, JS, Ramiro, S, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis 75 (2016), 499–510.
-
(2016)
Ann Rheum Dis
, vol.75
, pp. 499-510
-
-
Gossec, L.1
Smolen, J.S.2
Ramiro, S.3
-
9
-
-
84959912573
-
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 treatment recommendations for psoriatic arthritis
-
Coates, LC, Kavanaugh, A, Mease, PJ, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol 68 (2016), 1060–1071.
-
(2016)
Arthritis Rheumatol
, vol.68
, pp. 1060-1071
-
-
Coates, L.C.1
Kavanaugh, A.2
Mease, P.J.3
-
10
-
-
85016812795
-
Switching biologics in the treatment of psoriatic arthritis
-
Merola, JF, Lockshin, B, Mody, EA, Switching biologics in the treatment of psoriatic arthritis. Semin Arthritis Rheum 47 (2017), 29–37.
-
(2017)
Semin Arthritis Rheum
, vol.47
, pp. 29-37
-
-
Merola, J.F.1
Lockshin, B.2
Mody, E.A.3
-
11
-
-
84899083985
-
Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey
-
Lebwohl, MG, Bachelez, H, Barker, J, et al. Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. J Am Acad Dermatol 70 (2014), 871–881.
-
(2014)
J Am Acad Dermatol
, vol.70
, pp. 871-881
-
-
Lebwohl, M.G.1
Bachelez, H.2
Barker, J.3
-
12
-
-
84904638434
-
The molecular regulation of Janus kinase (JAK) activation
-
Babon, JJ, Lucet, IS, Murphy, JM, Nicola, NA, Varghese, LN, The molecular regulation of Janus kinase (JAK) activation. Biochem J 462 (2014), 1–13.
-
(2014)
Biochem J
, vol.462
, pp. 1-13
-
-
Babon, J.J.1
Lucet, I.S.2
Murphy, J.M.3
Nicola, N.A.4
Varghese, L.N.5
-
13
-
-
77955375143
-
Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis
-
Meyer, DM, Jesson, MI, Li, X, et al. Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. J Inflamm, 7, 2010, 41.
-
(2010)
J Inflamm
, vol.7
, pp. 41
-
-
Meyer, D.M.1
Jesson, M.I.2
Li, X.3
-
14
-
-
85031767309
-
Tofacitinib or adalimumab versus placebo for psoriatic arthritis
-
Mease, P, Hall, S, FitzGerald, O, et al. Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N Engl J Med 377 (2017), 1537–1550.
-
(2017)
N Engl J Med
, vol.377
, pp. 1537-1550
-
-
Mease, P.1
Hall, S.2
FitzGerald, O.3
-
15
-
-
85031800565
-
Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors
-
Gladman, D, Rigby, W, Azevedo, VF, et al. Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. N Engl J Med 377 (2017), 1525–1536.
-
(2017)
N Engl J Med
, vol.377
, pp. 1525-1536
-
-
Gladman, D.1
Rigby, W.2
Azevedo, V.F.3
-
16
-
-
85043338932
-
Efficacy and safety of biologics targeting interleukin-6, -12/23 and -17 pathways for peripheral psoriatic arthritis: a network meta-analysis
-
Wu, D, Yue, J, Tam, LS, Efficacy and safety of biologics targeting interleukin-6, -12/23 and -17 pathways for peripheral psoriatic arthritis: a network meta-analysis. Rheumatology 57 (2018), 563–571.
-
(2018)
Rheumatology
, vol.57
, pp. 563-571
-
-
Wu, D.1
Yue, J.2
Tam, L.S.3
-
17
-
-
84885103906
-
Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases
-
Van Rompaey, L, Galien, R, van der Aar, EM, et al. Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases. J Immunol 191 (2013), 3568–3577.
-
(2013)
J Immunol
, vol.191
, pp. 3568-3577
-
-
Van Rompaey, L.1
Galien, R.2
van der Aar, E.M.3
-
18
-
-
85055096499
-
OP0161 the JAK1 selective inhibitor filgotinib regulates both enthesis and colon inflammation in a mouse model of psoriatic arthritis
-
Robin-Jagerschmidt, C, Lavazais, S, Marsais, F, et al. OP0161 the JAK1 selective inhibitor filgotinib regulates both enthesis and colon inflammation in a mouse model of psoriatic arthritis. Ann Rheum Dis 76 (2017), 118–119.
-
(2017)
Ann Rheum Dis
, vol.76
, pp. 118-119
-
-
Robin-Jagerschmidt, C.1
Lavazais, S.2
Marsais, F.3
-
19
-
-
85007190313
-
Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2)
-
Kavanaugh, A, Kremer, J, Ponce, L, et al. Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2). Ann Rheum Dis 76 (2017), 1009–1019.
-
(2017)
Ann Rheum Dis
, vol.76
, pp. 1009-1019
-
-
Kavanaugh, A.1
Kremer, J.2
Ponce, L.3
-
20
-
-
85007236113
-
Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1)
-
Westhovens, R, Taylor, PC, Alten, R, et al. Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1). Ann Rheum Dis 76 (2017), 998–1008.
-
(2017)
Ann Rheum Dis
, vol.76
, pp. 998-1008
-
-
Westhovens, R.1
Taylor, P.C.2
Alten, R.3
-
21
-
-
85044253176
-
Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes
-
Genovese, M, Westhovens, R, Meuleners, L, et al. Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes. Arthritis Res Ther, 20, 2018, 57.
-
(2018)
Arthritis Res Ther
, vol.20
, pp. 57
-
-
Genovese, M.1
Westhovens, R.2
Meuleners, L.3
-
22
-
-
85008324875
-
Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial
-
Vermeire, S, Schreiber, S, Petryka, R, et al. Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial. Lancet 389 (2017), 266–275.
-
(2017)
Lancet
, vol.389
, pp. 266-275
-
-
Vermeire, S.1
Schreiber, S.2
Petryka, R.3
-
23
-
-
85055083813
-
Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial
-
published online Oct 22.
-
van der Heijde, D, Baraliakos, X, Gensler, LS, et al. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial. Lancet, 2018 published online Oct 22. http://dx.doi.org/10.1016/S0140-6736(18)32463-2.
-
(2018)
Lancet
-
-
van der Heijde, D.1
Baraliakos, X.2
Gensler, L.S.3
-
24
-
-
33746951437
-
Classification criteria for psoriatic arthritis: development of new criteria from a large international study
-
Taylor, W, Gladman, D, Helliwell, P, Marchesoni, A, Mease, P, Mielants, H, Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54 (2006), 2665–2673.
-
(2006)
Arthritis Rheum
, vol.54
, pp. 2665-2673
-
-
Taylor, W.1
Gladman, D.2
Helliwell, P.3
Marchesoni, A.4
Mease, P.5
Mielants, H.6
-
25
-
-
80155181447
-
Minimally important difference of Health Assessment Questionnaire in psoriatic arthritis: relating thresholds of improvement in functional ability to patient-rated importance and satisfaction
-
Mease, PJ, Woolley, JM, Bitman, B, Wang, BC, Globe, DR, Singh, A, Minimally important difference of Health Assessment Questionnaire in psoriatic arthritis: relating thresholds of improvement in functional ability to patient-rated importance and satisfaction. J Rheumatol 38 (2011), 2461–2465.
-
(2011)
J Rheumatol
, vol.38
, pp. 2461-2465
-
-
Mease, P.J.1
Woolley, J.M.2
Bitman, B.3
Wang, B.C.4
Globe, D.R.5
Singh, A.6
-
26
-
-
84908370285
-
Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis
-
Winthrop, KL, Yamanaka, H, Valdez, H, et al. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheumatol 66 (2014), 2675–2684.
-
(2014)
Arthritis Rheumatol
, vol.66
, pp. 2675-2684
-
-
Winthrop, K.L.1
Yamanaka, H.2
Valdez, H.3
-
27
-
-
85055117538
-
FDA Briefing document. NDA 207924 Baricitnib, a Janus kinase (JAK) inhibitor for RA
-
(Accessed 28 August 2018)
-
US Food and Drug Administration. FDA Briefing document. NDA 207924 Baricitnib, a Janus kinase (JAK) inhibitor for RA. https://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/arthritisadvisorycommittee/ucm605061.pdf, 2018. (Accessed 28 August 2018)
-
(2018)
-
-
-
28
-
-
85016146867
-
Review of the treatment of psoriatic arthritis with biological agents: choice of drug for initial therapy and switch therapy for non-responders
-
D'Angelo, S, Tramontano, G, Gilio, M, Leccese, P, Olivieri, I, Review of the treatment of psoriatic arthritis with biological agents: choice of drug for initial therapy and switch therapy for non-responders. Open Access Rheumatol 9 (2017), 21–28.
-
(2017)
Open Access Rheumatol
, vol.9
, pp. 21-28
-
-
D'Angelo, S.1
Tramontano, G.2
Gilio, M.3
Leccese, P.4
Olivieri, I.5
-
29
-
-
85047254944
-
Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study
-
Mease, P, van der Heijde, D, Landewé R, et al. Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study. Ann Rheum Dis 77 (2018), 890–897.
-
(2018)
Ann Rheum Dis
, vol.77
, pp. 890-897
-
-
Mease, P.1
van der Heijde, D.2
Landewé, R.3
-
30
-
-
84984629205
-
Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1
-
Mease, PJ, van der Heijde, D, Ritchlin, CT, et al. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis 76 (2017), 79–87.
-
(2017)
Ann Rheum Dis
, vol.76
, pp. 79-87
-
-
Mease, P.J.1
van der Heijde, D.2
Ritchlin, C.T.3
-
31
-
-
85046358073
-
Early and sustained efficacy with apremilast monotherapy in biological-naive patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE)
-
Nash, P, Ohson, K, Walsh, J, et al. Early and sustained efficacy with apremilast monotherapy in biological-naive patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE). Ann Rheum Dis 77 (2018), 690–698.
-
(2018)
Ann Rheum Dis
, vol.77
, pp. 690-698
-
-
Nash, P.1
Ohson, K.2
Walsh, J.3
-
32
-
-
85051453963
-
Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trial
-
Wells, AF, Edwards, CJ, Kivitz, AJ, et al. Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trial. Rheumatology 57 (2018), 1253–1263.
-
(2018)
Rheumatology
, vol.57
, pp. 1253-1263
-
-
Wells, A.F.1
Edwards, C.J.2
Kivitz, A.J.3
|